Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study

Conditions

• Glanzmann Thrombasthenia

Interventions

• OTHER: Clot formation in whole blood under flow in a microfluidic flow chamber coated with tissue factor and collagen
• OTHER: : PRP viscoelastic changes under clot formation measured by thromboelastometry using RoTEM
• OTHER: Thrombin Generation Assay (TGA) in PRP using TF trigger
• OTHER: Global fibrinolytic capacity in PRP using reagents for in vitro triggering of the clot and its lysis
• OTHER: Concizumab

Sponsor

University Hospital, Bordeaux